ADK-591АДК-591
ADK-591 is an experimental N-substituted adamantylpiperazine. A historical screen reported weak inhibition of hepatic monooxygenases, enzymes involved in drug metabolism. The source does not identify the N-substituent.
What the studies found
Animal research · 1996
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
Findings for this preparation
ADK-591 was described as a weak inhibitor of hepatic monooxygenases in the historical experimental screen. These findings do not establish a human clinical effect.
Study notes · methods, sources and limitations
Participants or model Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
Important limitations
- Original structures and tables require checking against the scan; transcription errors are possible. Enzyme induction does not establish detoxification benefits or predict safe human drug combinations. Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.
Doctoral dissertation author’s abstract. Moscow, 1996 · Dissertation; OCR reproduction
About ADK-591
Research background
An N-substituted adamantylpiperazine in the historical hepatic-enzyme screen. Exact substitution requires recovery of the original structural record.
- Compound class
- Archival adamantane screening lead
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Human efficacy results unavailable
Study methods
Source-specific animal, chemistry, patent or dissertation evidence
Independent replication
Independent replication not established; translations are not separate experiments
Source access
Access and review depth appear with each linked record
Safety evidence
Human safety and interactions not established; animal activity is not a safe-use recommendation
Open a topic for the evidence assessment.
Findings by study
Animal research · 1996
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
ADK-591 was described as a weak inhibitor of hepatic monooxygenases in the historical experimental screen. These findings do not establish a human clinical effect.
Study notes and original source
Influence of hereditary and environmental factors on cytochrome P450 metabolic activity and drug effects
· Dissertation; OCR reproduction
Format: Dissertation abstract transcription · Reviewed: See scope
T. G. Khlopushina · Doctoral dissertation author’s abstract. Moscow, 1996
ADK-559/591/676/677 weakly inhibited hepatic monooxygenases; ADK-709/790/828/829/910/918 induced P450. The author also reports fewer anaphylaxis deaths with ADK-828 and ADK-829 in guinea pigs. Different controls and OCR table ambiguities prevent a reliable cross-compound ranking.
- Population / setting
- Mouse hepatic-enzyme screening and sensitized guinea-pig anaphylaxis experiments
- Source reviewed
- Selected source passages checked; complete methods and risk of bias not appraised.
Study limitations
- Original structures and tables require checking against the scan; transcription errors are possible.
- Enzyme induction does not establish detoxification benefits or predict safe human drug combinations.
- Animal anaphylaxis results are not evidence for treating allergy in people; proposed adjunct uses were development suggestions.
Reviewed 2026-10-03.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗